FDA proposes new rule to streamline registration of drug manufacturers' factories

The FDA announced a proposed rule aimed at changing how factories that produce drugs for the U.S. market are registered with the agency.

The change is intended to simplify the registration process for both domestic and foreign facilities, reducing administrative burden and potentially speeding product availability.

The agency said the proposal is part of ongoing efforts to modernize its regulatory framework and will be open for public comment before finalization.